Arcturus Therapeutics Holdings Inc. Cash Flow Statement
ARCT|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$74M
FY2025
Free Cash Flow
-$75M
FY2025
Capital Expenditures
$230,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Arcturus Therapeutics Holdings Inc. used $74M in operating cash flow and negative free cash flow of $75M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$65.8M | -$80.9M | -$29.7M | -$203.7M | -$203.7M | -$21.8M | -$21.8M |
| Depreciation & Amortization | $3.0M | $3.5M | $3.0M | $1.2M | $1.2M | $582.0K | $582.0K |
| Operating Cash Flow | -$74.3M | -$59.7M | -$18.1M | -$135.0M | -$135.0M | -$20.8M | -$20.8M |
| Capital Expenditures | $230.0K | $648.0K | $2.9M | $3.4M | $3.4M | $1.5M | $1.5M |
| Free Cash Flow | -$74.5M | -$60.4M | -$21.0M | -$138.4M | -$138.4M | -$22.2M | -$22.2M |
| FCF Margin | -90.8% | -39.6% | -12.6% | -1120.2% | -1120.2% | -141.2% | -141.2% |